INDICATION
VEKLURY® (remdesivir) is indicated for the treatment of COVID-19 in adults and pediatric patients ≥12 years old and weighing ≥40 kg with positive results of SARS-CoV-2 viral testing, who are:
•   Hospitalized, or
•   Not hospitalized, have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

IMPORTANT SAFETY INFORMATION
Contraindication
•   VEKLURY is contraindicated in patients with a history of clinically significant hypersensitivity reactions to VEKLURY or any of its components.

Please see additional Important Safety Information throughout and click to see full Prescribing Information for VEKLURY.
Contents

NDC and ICD-10 codes

HCPCS and CPT codes

New COVID-19 Treatments Add-On Payment (NCTAP) Program

Disclaimer: Information provided in this resource is for informational purposes only and does not guarantee that codes will be appropriate or that coverage and reimbursement will result. Customers should consult with their payers for all relevant coverage, coding, and reimbursement requirements. It is the sole responsibility of the provider to select proper codes and ensure the accuracy of all claims used in seeking reimbursement. This resource is not intended to be legal advice or a substitute for a provider’s independent professional judgement.

IMPORTANT SAFETY INFORMATION (cont’d)

Warnings and precautions

• Hypersensitivity, including infusion-related and anaphylactic reactions: Hypersensitivity, including infusion-related and anaphylactic reactions, has been observed during and following administration of VEKLURY; most occurred within 1 hour. Monitor patients during infusion and observe for at least 1 hour after infusion is complete for signs and symptoms of hypersensitivity as clinically appropriate. Symptoms may include hypotension, hypertension, tachycardia, bradycardia, hypoxia, fever, dyspnea, wheezing, angioedema, rash, nausea, diaphoresis, and shivering. Slower infusion rates (maximum infusion time of up to 120 minutes) can potentially prevent these reactions. If a severe infusion-related hypersensitivity reaction occurs, immediately discontinue VEKLURY and initiate appropriate treatment (see Contraindications).

Please see additional Important Safety Information throughout and click to see full Prescribing Information for VEKLURY.
NDC and ICD-10 codes

<table>
<thead>
<tr>
<th>NDC¹</th>
<th>VEKLURY® (remdesivir) 100 mg for injection, lyophilized powder</th>
<th>VEKLURY® (remdesivir) 100 mg/20 mL (5 mg/mL) injection, solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-digit code</td>
<td>61958-2901-2</td>
<td>61958-2902-2</td>
</tr>
<tr>
<td>11-digit code</td>
<td>61958-2901-02</td>
<td>61958-2902-02</td>
</tr>
</tbody>
</table>

Payer requirements regarding the use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference. Please consult with the payer to understand specific billing requirements.

The ICD-10-CM diagnostic code²

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>U07.1</td>
<td>For discharges on or after April 1, 2020, continuing through the rest of the COVID-19 PHE period</td>
</tr>
</tbody>
</table>

ICD-10-PCS codes for VEKLURY²

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>XW033E5</td>
<td>Introduction of remdesivir anti-infective into peripheral vein, percutaneous approach, new technology group 5</td>
</tr>
<tr>
<td>XW043E5</td>
<td>Introduction of remdesivir anti-infective into central vein, percutaneous approach, new technology group 5</td>
</tr>
</tbody>
</table>

For hospital discharges on or after November 2, 2020.

IMPORTANT SAFETY INFORMATION (cont’d)

Warnings and precautions (cont’d)

• **Increased risk of transaminase elevations:** Transaminase elevations have been observed in healthy volunteers and in patients with COVID-19 who received VEKLURY; these elevations have also been reported as a clinical feature of COVID-19. Perform hepatic laboratory testing in all patients (see Dosage and administration). Consider discontinuing VEKLURY if ALT levels increase to >10x ULN. Discontinue VEKLURY if ALT elevation is accompanied by signs or symptoms of liver inflammation.

Please see additional Important Safety Information throughout and click to see full [Prescribing Information](#) for VEKLURY.

## IMPORTANT SAFETY INFORMATION (cont’d)

### Warnings and precautions (cont’d)

- **Risk of reduced antiviral activity when coadministered with chloroquine or hydroxychloroquine:**
  
  Coadministration of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended based on data from cell culture experiments, demonstrating potential antagonism, which may lead to a decrease in the antiviral activity of VEKLURY.

Please see additional Important Safety Information throughout and click to see full [Prescribing Information](#) for VEKLURY.


### HCPCS and CPT codes

#### HCPCS code

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0248</td>
<td>Long: Injection, remdesivir, 1 mg&lt;br&gt;Short: Inj, remdesivir, 1 mg</td>
<td>The Centers for Medicare &amp; Medicaid Services (CMS) assigned the HCPCS code J0248 for VEKLURY® antiviral medication when administered in an outpatient setting. This code is available for all payers and is effective for dates of service on or after December 23, 2021.</td>
</tr>
</tbody>
</table>

HCPCS coding requirements will vary by payer, setting of care, and date of service. Please verify patient-specific insurance benefits to confirm specific coding and billing guidelines for VEKLURY.

#### CPT codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>96365</td>
<td>Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour</td>
</tr>
<tr>
<td>96366</td>
<td>Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>96367</td>
<td>Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>96368</td>
<td>Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (list separately in addition to code for primary procedure)</td>
</tr>
</tbody>
</table>
CMS provides enhanced payments for eligible inpatient COVID-19 cases that involve the use of VEKLURY®

New COVID-19 Treatments Add-On Payment (NCTAP) program

- CMS provides a payment enhancement under the NCTAP program for eligible hospital inpatient cases that involve the use of certain new products or treatments with current FDA approval or an EUA to treat COVID-19, including VEKLURY®

- NCTAP, which was designed to mitigate potential financial disincentives for hospitals to provide new COVID-19 treatments, is effective from November 2, 2020, until the end of the fiscal year in which the COVID-19 public health emergency (PHE) ends.

Click here or visit the CMS website to learn more about NCTAP.

Medicare DRG enhancement for COVID-19 cases

- Section 3710 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act provides for an increase in the weighting factor for an assigned DRG by 20% for an individual diagnosed with COVID-19 and discharged during the PHE.

- CMS requires a positive COVID-19 test in order for these Medicare claims to be eligible for the 20% increase in Medicare Severity DRG weighting factor.

*Including the adjustment to the relative weight under Section 3710 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act.

The details provided are for general reimbursement information only and are not legal advice nor are they advice about how to code, complete, or submit any particular claim for payment. Information provided is not intended to increase or maximize reimbursement.

**IMPORTANT SAFETY INFORMATION** (cont’d)

Adverse reactions
- The most common adverse reaction (≥5% all grades) was nausea.
- The most common lab abnormalities (≥5% all grades) were increases in ALT and AST.

Drug interactions
- Drug interaction trials of VEKLURY and other concomitant medications have not been conducted in humans.

Dosage and administration
- **Dosage:** For adults and pediatric patients ≥12 years old and weighing ≥40 kg: 200 mg on Day 1, followed by once-daily maintenance doses of 100 mg from Day 2 administered only via intravenous infusion. VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19.

Please see additional Important Safety Information throughout and click to see full Prescribing Information for VEKLURY.

EUA = Emergency Use Authorization.
IMPORTANT SAFETY INFORMATION (cont’d)

Dosage and administration (cont’d)

• Treatment duration:
  - For patients who are hospitalized and require invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 10 days.
  - For patients who are hospitalized and do not require invasive mechanical ventilation and/or ECMO, the recommended treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days, for a total treatment duration of up to 10 days.
  - For patients who are not hospitalized, diagnosed with mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death, the recommended total treatment duration is 3 days.

• Testing prior to and during treatment: Perform eGFR, hepatic laboratory, and prothrombin time testing prior to initiating VEKLURY and during use as clinically appropriate.

• Renal impairment: VEKLURY is not recommended in individuals with eGFR <30 mL/min.

• Dose preparation and administration: See full Prescribing Information.

Pregnancy and lactation

• Pregnancy: A pregnancy registry has been established. There are insufficient human data on the use of VEKLURY during pregnancy. COVID-19 is associated with adverse maternal and fetal outcomes, including preeclampsia, eclampsia, preterm birth, premature rupture of membranes, venous thromboembolic disease, and fetal death.

• Lactation: It is not known whether VEKLURY can pass into breast milk. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.

Please see additional Important Safety Information throughout and click to see full Prescribing Information for VEKLURY.